Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treprostinil - United Therapeutics Corporation

X
Drug Profile

Treprostinil - United Therapeutics Corporation

Alternative Names: TD-300 TYVASO® Inhalation System; 15AU; 15AU81; ARD-1500; ARD-1550; BW 15AU; BW 15AU81; BW A15AU; LRX 15; MD 711; MD-0701; OreniCell; OreniLeft; Orenitram; Remodulin; Sustained-release treprostinil - United Therapeutics; TD-100 TYVASO® Inhalation System; TransCon treprostinil; Treprost; Treprostenol; Treprostinil diolamine; Treprostinol; Tresprostinol diethanolamine; Tyvaso; U 62840; Uniprost; UT 15; UT-15C; UT-15C SR

Latest Information Update: 21 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Pfizer
  • Developer AOP Orphan Pharmaceuticals AG; Ascendis Pharma; Ferrer; Lee's Pharmaceutical; Mochida Pharmaceutical; United Therapeutics Corporation
  • Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension; Pulmonary hypertension
  • Phase III Idiopathic pulmonary fibrosis
  • Phase II Systemic scleroderma
  • Discontinued Cancer; Chronic limb-threatening ischemia; Heart failure

Most Recent Events

  • 10 Jul 2024 United Therapeutics completes enrolment from its Phase-III clinical trials in Idiopathic pulmonary fibrosis in Argentina, Australia, Belgium, Chile, Denmark, France, Germany, Israel, Italy, Mexico, Netherlands, New Zealand, Peru, Spain, Taiwan, South Korea (Inhalation) (NCT05255991)
  • 09 Jul 2024 Phase-III clinical trials in Idiopathic pulmonary fibrosis in Peru, Germany (Inhalation) (NCT05255991)
  • 09 Jul 2024 United Therapeutics initiates a Phase-III clinical trials in Idiopathic pulmonary fibrosis in Belgium, Italy, Mexico, Netherlands, New Zealand (Inhalation) (NCT05255991)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top